<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04889495</url>
  </required_header>
  <id_info>
    <org_study_id>B7391012</org_study_id>
    <nct_id>NCT04889495</nct_id>
  </id_info>
  <brief_title>A Post-marketing Surveillance to Assess the Safety and Effectiveness of Zirabev in Domestic Patients With Various Cancer</brief_title>
  <official_title>A Prospective, Single-arm, Open-label, Non-interventional, Multicenter, Post-marketing Surveillance to Assess the Safety and Effectiveness of Zirabev in Domestic Patients With Non-small Cell Lung Cancer, Metastatic Colorectal Cancer, Metastatic Breast Cancer, Advanced or Metastatic Kidney Cancer, Cervical Cancer, Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer or Glioblastoma Multiforme.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <brief_summary>
    <textblock>
      This is a prospective, single-arm, open-label, non-interventional, multicenter,&#xD;
      post-marketing surveillance to assess the safety and effectiveness of Zirabev(Bevacizumab&#xD;
      biosimilar) in domestic patients with non-small cell lung cancer, metastatic colorectal&#xD;
      cancer, metastatic breast cancer, advanced or metastatic kidney cancer, cervical cancer,&#xD;
      epithelial ovarian cancer, fallopian tube cancer, primary peritoneal cancer or glioblastoma&#xD;
      multiforme.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 31, 2023</start_date>
  <completion_date type="Anticipated">August 16, 2025</completion_date>
  <primary_completion_date type="Anticipated">August 1, 2024</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Safety profile</measure>
    <time_frame>baseline up to approximately 4 years</time_frame>
    <description>The following items that occurred from the baseline:&#xD;
Adverse Events (AEs)&#xD;
Serious Adverse Events (SAEs)&#xD;
Expected Adverse Events (Expected AEs)&#xD;
Unexpected Adverse Events (Unexpected AEs)&#xD;
Adverse Drug Reactions (ADRs)&#xD;
Serious Adverse Drug Reactions (SADRs)&#xD;
Expected Adverse Drug Reactions (Expected ADR)&#xD;
Unexpected Adverse Drug Reactions (Unexpected ADR)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy profile</measure>
    <time_frame>baseline up to approximately 4 years</time_frame>
    <description>OR CR SD PD&#xD;
Non-small cell lung cancer, metastatic colorectal cancer, metastatic breast cancer, advanced or metastatic kidney cancer, cervical cancer, epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer&#xD;
• Four objective response categories: complete response (CR), partial response (PR), stable disease (SD), progressive disease (PD) (RECIST 1.1)&#xD;
Glioblastoma multiforme patients • Four objective response categories: complete response (CR), partial response (PR), stable disease (SD), progressive disease (PD) (RANO-HGG)</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Non-small Cell Lung Cancer</condition>
  <condition>Metastatic Colorectal Cancer</condition>
  <condition>Metastatic Breast Cancer</condition>
  <condition>Metastatic Kidney Cancer</condition>
  <condition>Cervical Cancer</condition>
  <condition>Epithelial Ovarian Cancer</condition>
  <condition>Fallopian Tube Cancer</condition>
  <condition>Primary Peritoneal Cancer</condition>
  <arm_group>
    <arm_group_label>Participants receiving Zirabev</arm_group_label>
    <description>Participants receiving Zirabev</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zirabev</intervention_name>
    <description>Bevacizumab biosimilar</description>
    <arm_group_label>Participants receiving Zirabev</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        See below&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        - Inclusion criteria&#xD;
&#xD;
        Patients must meet all of the following inclusion criteria to be eligible for inclusion in&#xD;
        the study:&#xD;
&#xD;
          1. Adults over 19 years old&#xD;
&#xD;
          2. Patients with non-small cell lung cancer, metastatic colorectal cancer, metastatic&#xD;
             breast cancer, advanced or metastatic kidney cancer, cervical cancer, epithelial&#xD;
             ovarian cancer, fallopian tube cancer, primary peritoneal cancer or glioblastoma&#xD;
             multiforme.&#xD;
&#xD;
          3. Patients eligible for Zirabev dosage based on local product document, local treatment&#xD;
             guidelines and clinical judgment of the medical team.&#xD;
&#xD;
          4. Evidence of a signed and dated informed consent document indicating that the patient&#xD;
             (or a legally acceptable representative) has been informed of all pertinent aspects of&#xD;
             the study.&#xD;
&#xD;
               -  Exclusion criteria&#xD;
&#xD;
        Patients meeting any of the following criteria will not be included in the study:&#xD;
&#xD;
          1. Any patients (or a legally acceptable representative) who does not agree that Pfizer&#xD;
             and companies working with Pfizer use his/her information.&#xD;
&#xD;
          2. Patients for whom Zirabev is contraindicated according to the local product document.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <phone>1-800-718-1021</phone>
    <email>ClinicalTrials.gov_Inquiries@pfizer.com</email>
  </overall_contact>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>May 12, 2021</study_first_submitted>
  <study_first_submitted_qc>May 12, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 17, 2021</study_first_posted>
  <last_update_submitted>October 5, 2021</last_update_submitted>
  <last_update_submitted_qc>October 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Zirabev</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
    <mesh_term>Colorectal Neoplasms</mesh_term>
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Ovarian Epithelial</mesh_term>
    <mesh_term>Uterine Cervical Neoplasms</mesh_term>
    <mesh_term>Fallopian Tube Neoplasms</mesh_term>
    <mesh_term>Kidney Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

